A Missed Opportunity: ALS Research Funding Absent from the 2026 Federal Budget

Taking the call for action to Parliament Hill

ALS Action Canada is deeply disappointed that the 2026 federal budget failed to include a proposed $50 million investment over five years in the Canadian Collaboration to Cure ALS — a critical opportunity to accelerate ALS research, clinical trials and collaboration across Canada.

ALS Action Canada recently joined partners from the Canadian Coalition to End ALS on Parliament Hill in Ottawa to advocate for a federal investment of $50 million over five years in the Canadian Collaboration to Cure ALS.

Led by ALS Canada, this coordinated advocacy initiative brought together people living with ALS, caregivers, advocates and organizations from across the country to call for greater federal investment in ALS research.

The proposed investment builds on years of advocacy efforts to secure sustained federal support for ALS research and bring together Canadian expertise, resources and innovation to accelerate progress toward effective treatments and, ultimately, a cure.

Alongside our coalition partners, ALS Action Canada helped bring the urgency of this investment directly to federal decision-makers.

The message was clear: Canadians living with ALS need meaningful federal leadership and investment to accelerate research and improve the prospects for future treatments.

A critical investment left out of the federal budget

Despite these advocacy efforts, the proposed funding commitment was not included in the 2026 federal budget.

ALS Action Canada is deeply disappointed by this decision.

For Canadians living with ALS and their families, time is not a luxury. ALS is a progressive, terminal disease, and the need for effective treatments is urgent.

Investment in research, clinical trials and collaboration is essential to advancing scientific discoveries and translating them into treatments that can make a meaningful difference.

The absence of this funding represents a missed opportunity to strengthen Canada’s contribution to ALS research and risks leaving the country further behind international efforts to accelerate progress.

The personal impact behind the call for action

For ALS Action Canada Board Director Cali Orsulak, the need for greater investment is deeply personal. Her late husband, Kenny, lived with ALS, giving her firsthand experience of the devastating impact of the disease and the limited treatment options available to families.

Cali reflects on the importance of sustained investment and the opportunity represented by the Canadian Collaboration to Cure ALS:

“As a physician and pharmacist couple, we understood that decades of underinvestment in ALS research had left families with far too few treatment options and little hope. We knew things needed to change. The Canadian Collaboration to Cure ALS is an opportunity to unite Canadian expertise and innovation to accelerate the discovery of effective treatments. While deeply disappointed by this missed funding opportunity, we will continue advocating for the investment ALS families deserve. Canadians living with ALS deserve more than hope; they deserve action.”

— Cali Orsulak, ALS Action Canada Board Director

Her perspective reinforces why people with lived experience must remain central to decisions about ALS research priorities and public investment.

Our advocacy continues

While the 2026 federal budget represents a missed opportunity, the need for action has not changed.

ALS Action Canada will continue working alongside our partners in the Canadian Coalition to End ALS and the broader ALS community to advocate for the federal investment needed to advance research, strengthen collaboration and accelerate progress toward effective treatments.

We recognize ALS Canada’s leadership in bringing organizations, advocates and people affected by ALS together around this important national initiative.

Canadians living with ALS deserve more than hope. They deserve action.

ALS doesn’t wait. Neither do we.

Facebook
LinkedIn

Explore more

Bringing the ALS Patient Perspective to Canada’s Drug Policy Reform Debate

ALS Action Canada Member Dr. Andrew Darke, who is living with ALS, is contributing to the national debate on drug policy reform. In a Financial Post commentary with Nigel Rawson and John Adams, he examines how recent U.S. trade policies strengthen the case for reforms to Canada’s drug approval, pricing and coverage processes. For ALS Action Canada, advocating for timely and equitable access to innovative treatments remains a key priority.

Read More »

A Patient Perspective on ALS Clinical Trials and Timely Access

How much evidence should be required before people living with ALS can access a promising new therapy?

In a newly published Reader Response in Neurology, Dr. Andrew Darke, an ALS Action Canada Advocacy Committee Member, responds to a recent article examining what its authors describe as a “credibility gap” in ALS clinical trials, due to what it describes as a “Clinical Trial Industrial Complex” involving ALS neurologists and manufacturers of new drugs for ALS.

Read More »